News | November 21, 2023
AstraZeneca launches health-tech business ‘Evinova’
Evinova will operate as a separate health-tech business within AstraZeneca
Evinova will operate as a separate health-tech business within AstraZeneca
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
The company has raised US$4.5 million in funding for its AI operating system
This product will be manufactured at Lupin’s Pithampur facility in India
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Subscribe To Our Newsletter & Stay Updated
